Interventions for Pulmonary Vein Stenosis

Sophia Hsien1, Usha Krishnan1, Christopher J Petit1

  • 1Division of Pediatric Cardiology, New York Presbyterian Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA.

Insights

Pulmonary vein stenosis (PVS) in children is a serious condition. Recent interventional and systemic therapies have improved outcomes, but PVS often recurs, requiring ongoing management.

Area of Science:

  • Pediatric Cardiology
  • Interventional Pulmonology
  • Rare Diseases

Background:

  • Pulmonary vein stenosis (PVS) is a rare pediatric condition with high morbidity and mortality.
  • Effective treatments for PVS have historically been limited.
  • Recent advancements show promise in managing this challenging disease.

Purpose of the Study:

  • To review current interventional techniques for pediatric pulmonary vein stenosis.
  • To discuss the combination of interventional and systemic therapies.
  • To share collective experiences and practices in managing PVS.

Main Methods:

  • Review of state-of-the-art interventional techniques.
  • Analysis of outcomes combining interventional and systemic therapies.
  • Discussion based on collective clinical experience.

Main Results:

  • Interventional techniques combined with systemic therapy have significantly improved outcomes for children with PVS.
  • Despite initial relief, stenosis reliably recurs and progresses.
  • Ongoing management and advanced techniques are crucial.

Conclusions:

  • Combined interventional and systemic therapy offers a remarkable impact on PVS outcomes.
  • Recurrence and progression of PVS necessitate continued therapeutic strategies.
  • This review highlights current best practices for managing pediatric PVS.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
139
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
197
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K